Primary Sclerosing Cholangitis Market is expected to rise gradually to an estimated value of USD 157.13 million by 2026, registering a CAGR of 3.7% in the forecast period of 2019-2026 with the annual sales of USD 117.5 million in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
Key Market Competitors:
Few of the major competitors currently working in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), NGM Biopharmaceuticals (US), Intercept Pharmaceuticals, Inc. (US), Dr. Falk Pharma GmbH (Germany), ALLERGAN (Ireland), Takeda Pharmaceutical Company Limited. (Japan), DURECT CORPORATION (US), Conatus Pharmaceuticals, Inc. (US), Sirnaomics, Inc. (US), and HighTide Therapeutics Inc. (China), Glenmark (India), Impax Laboratories, LLC (US), Mylan N.V. (US), Teva Pharmaceuticals Industries Ltd. (Israel) and few among others.
Ask For Complimentary Sample PDF | Request At https://databridgemarketresearch.com/request-a-sample/?dbmr=global-primary-sclerosing-cholangitis-market
Insights of the report
- What are the challenges being faced by the new entrants
- Drivers and restrains of the market
- To inspect the market based on product, market share and size of the product share.
- Recent industry trends and developments
- Potential and niche segments/regions exhibiting promising growth
Rise in incidence and prevalence rate of liver failure and bile cancer associated with PSC.
Large No. of pipeline molecules is expected to drive the growth of the market.
Withdrawal of novel molecules from late stage clinical trials will restrain the growth of the market.
Organ transplantation remains the alternative which is associated with many risk factors like relapse of the disease.
Lack of skilled expertise in remote areas
Fewer Government initiatives taken in this direction.
Table of Contents
5.Global, By Component
PSC associated with autoimmune hepatitis
By Treatment Type
By Symptom Control
By End- User
Middle East & Africa
Key Developments in the Market:
On 19th January, 2016, Acorda Therapeutics, Inc. announced that it entered into an agreement to acquire Biotie Therapies Corp. According to the agreement, the company will acquire the four pipeline products that include BTT1023, a fully human monoclonal antibody in Phase 2 development for treatment of primary sclerosing cholangitis (PSC) which will help company to grow.
On 27th March, 2019, Gilead Sciences, Inc. announced the company’s research and development programs in primary sclerosing cholangitis (PSC) will be presented at The International Liver Congress™ 2019 in Vienna. Currently the novel molecule, Cilofexor has not get the approval but once it gets approval it will generate the revenue for the company and contribute towards the growth of the market.
Inquiry For Customize Report With Discount at : https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-primary-sclerosing-cholangitis-market
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
Email: [email protected]